These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 10996633)

  • 21. Dendritic cell-based immunotherapy for prostate cancer.
    Tjoa BA; Lodge PA; Salgaller ML; Boynton AL; Murphy GP
    CA Cancer J Clin; 1999; 49(2):117-28, 65. PubMed ID: 11198886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cell vaccines for the treatment of prostate cancer.
    Lehrfeld TJ; Lee DI
    Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer.
    Ragde H; Cavanagh WA; Tjoa BA
    J Urol; 2004 Dec; 172(6 Pt 2):2532-8. PubMed ID: 15538202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
    Aguilar LK; Guzik BW; Aguilar-Cordova E
    J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
    Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
    Front Immunol; 2021; 12():623639. PubMed ID: 33692796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of dendritic cell-based vaccines for cancer therapy.
    Reinhard G; Märten A; Kiske SM; Feil F; Bieber T; Schmidt-Wolf IG
    Br J Cancer; 2002 May; 86(10):1529-33. PubMed ID: 12085199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.
    Heiser A; Coleman D; Dannull J; Yancey D; Maurice MA; Lallas CD; Dahm P; Niedzwiecki D; Gilboa E; Vieweg J
    J Clin Invest; 2002 Feb; 109(3):409-17. PubMed ID: 11828001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer.
    Fishman M
    Expert Opin Biol Ther; 2009 Dec; 9(12):1565-75. PubMed ID: 19916735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immunotherapy of prostate and bladder cancer.
    Totterman TH; Loskog A; Essand M
    BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
    Arlen PM; Gulley JL; Tsang KY; Schlom J
    Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DCs in lymphoma--biology and therapeutic aspects.
    Schultze JL; Fiore F; von Bergwelt-Baildon M
    Cytotherapy; 2004; 6(2):138-47. PubMed ID: 15203990
    [No Abstract]   [Full Text] [Related]  

  • 34. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers for the development of cancer vaccines: current status.
    Copier J; Whelan M; Dalgleish A
    Mol Diagn Ther; 2006; 10(6):337-43. PubMed ID: 17154650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome.
    Slovin SF
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):972-80. PubMed ID: 18277959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer: advances in immunotherapy.
    Hurwitz AA; Yanover P; Markowitz M; Allison JP; Kwon ED
    BioDrugs; 2003; 17(2):131-8. PubMed ID: 12641491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
    Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
    Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cancer immunotherapy--current status].
    Kundig TM; Renner Ch; Knuth A
    Ther Umsch; 2006 Apr; 63(4):262-6. PubMed ID: 16689457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer vaccines based on dendritic cells loaded with tumor-associated antigens.
    Burdin N; Moingeon P
    Cell Biol Toxicol; 2001; 17(2):67-75. PubMed ID: 11499697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.